Gbola Amusa
Stock Analyst at Chardan Capital
(2.04)
# 2,718
Out of 4,818 analysts
61
Total ratings
40%
Success rate
2.87%
Average return
Main Sectors:
Stocks Rated by Gbola Amusa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $200 → $50 | $2.87 | +1,642.16% | 2 | Apr 29, 2021 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $60 → $68 | $1.81 | +3,629.28% | 3 | Apr 13, 2021 | |
| FBRX Forte Biosciences | Maintains: Buy | $2,875 → $2,625 | $6.02 | +43,504.65% | 4 | Mar 17, 2021 | |
| SLDB Solid Biosciences | Maintains: Buy | $188 → $300 | $3.56 | +8,326.97% | 5 | Mar 16, 2021 | |
| PASG Passage Bio | Maintains: Buy | $36 → $45 | $0.34 | +13,292.86% | 3 | Mar 8, 2021 | |
| MCRB Seres Therapeutics | Upgrades: Buy | $550 → $600 | $9.80 | +6,022.45% | 2 | Mar 5, 2021 | |
| QURE uniQure | Maintains: Buy | $85 → $100 | $14.39 | +594.93% | 4 | Mar 2, 2021 | |
| SYBX Synlogic | Maintains: Buy | $75 → $150 | $1.15 | +12,943.48% | 2 | Jan 13, 2021 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $53 → $50 | $3.19 | +1,467.40% | 3 | Oct 6, 2020 | |
| IMVT Immunovant | Maintains: Buy | $35 → $45 | $14.45 | +211.53% | 3 | Aug 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $115 | $165.80 | -30.64% | 2 | Aug 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $100 | $38.54 | +159.47% | 1 | Jul 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $95 | $26.54 | +257.95% | 2 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 → $15 | $7.11 | +110.97% | 4 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $130 | $8.90 | +1,360.67% | 4 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $100 | $0.94 | +10,538.30% | 6 | Mar 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $2.5 → $2 | $576.90 | -99.65% | 2 | Jan 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $7.64 | - | 3 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $300 → $350 | $587.85 | -40.46% | 6 | Dec 12, 2016 |
Adverum Biotechnologies
Apr 29, 2021
Downgrades: Neutral
Price Target: $200 → $50
Current: $2.87
Upside: +1,642.16%
Taysha Gene Therapies
Apr 13, 2021
Maintains: Buy
Price Target: $60 → $68
Current: $1.81
Upside: +3,629.28%
Forte Biosciences
Mar 17, 2021
Maintains: Buy
Price Target: $2,875 → $2,625
Current: $6.02
Upside: +43,504.65%
Solid Biosciences
Mar 16, 2021
Maintains: Buy
Price Target: $188 → $300
Current: $3.56
Upside: +8,326.97%
Passage Bio
Mar 8, 2021
Maintains: Buy
Price Target: $36 → $45
Current: $0.34
Upside: +13,292.86%
Seres Therapeutics
Mar 5, 2021
Upgrades: Buy
Price Target: $550 → $600
Current: $9.80
Upside: +6,022.45%
uniQure
Mar 2, 2021
Maintains: Buy
Price Target: $85 → $100
Current: $14.39
Upside: +594.93%
Synlogic
Jan 13, 2021
Maintains: Buy
Price Target: $75 → $150
Current: $1.15
Upside: +12,943.48%
Iovance Biotherapeutics
Oct 6, 2020
Maintains: Buy
Price Target: $53 → $50
Current: $3.19
Upside: +1,467.40%
Immunovant
Aug 25, 2020
Maintains: Buy
Price Target: $35 → $45
Current: $14.45
Upside: +211.53%
Aug 19, 2020
Maintains: Buy
Price Target: $100 → $115
Current: $165.80
Upside: -30.64%
Jul 28, 2020
Maintains: Buy
Price Target: $73 → $100
Current: $38.54
Upside: +159.47%
Jul 15, 2020
Maintains: Buy
Price Target: $84 → $95
Current: $26.54
Upside: +257.95%
Aug 17, 2018
Downgrades: Neutral
Price Target: $19 → $15
Current: $7.11
Upside: +110.97%
Jul 16, 2018
Maintains: Buy
Price Target: $90 → $130
Current: $8.90
Upside: +1,360.67%
Mar 27, 2018
Maintains: Neutral
Price Target: $75 → $100
Current: $0.94
Upside: +10,538.30%
Jan 10, 2018
Upgrades: Neutral
Price Target: $2.5 → $2
Current: $576.90
Upside: -99.65%
Nov 10, 2017
Upgrades: Buy
Price Target: n/a
Current: $7.64
Upside: -
Dec 12, 2016
Upgrades: Neutral
Price Target: $300 → $350
Current: $587.85
Upside: -40.46%